COMBI Stock Overview
Engages in the development of gene therapy for severe life-altering diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CombiGene AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.72 |
| 52 Week High | SEK 4.30 |
| 52 Week Low | SEK 1.27 |
| Beta | 1.48 |
| 1 Month Change | 6.25% |
| 3 Month Change | 10.57% |
| 1 Year Change | -0.73% |
| 3 Year Change | -76.95% |
| 5 Year Change | -87.64% |
| Change since IPO | -98.48% |
Recent News & Updates
Shareholder Returns
| COMBI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.7% | 1.2% | -2.7% |
| 1Y | -0.7% | 13.8% | 4.6% |
Return vs Industry: COMBI underperformed the Swedish Biotechs industry which returned 13.8% over the past year.
Return vs Market: COMBI underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| COMBI volatility | |
|---|---|
| COMBI Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: COMBI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: COMBI's weekly volatility has increased from 11% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 9 | Peter Ekolind | www.combigene.com |
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures.
CombiGene AB (publ) Fundamentals Summary
| COMBI fundamental statistics | |
|---|---|
| Market cap | SEK 53.86m |
| Earnings (TTM) | -SEK 37.08m |
| Revenue (TTM) | SEK 3.15m |
17.1x
P/S Ratio-1.5x
P/E RatioIs COMBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COMBI income statement (TTM) | |
|---|---|
| Revenue | SEK 3.15m |
| Cost of Revenue | SEK 22.01m |
| Gross Profit | -SEK 18.86m |
| Other Expenses | SEK 18.22m |
| Earnings | -SEK 37.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -1.87 |
| Gross Margin | -599.71% |
| Net Profit Margin | -1,179.02% |
| Debt/Equity Ratio | 0% |
How did COMBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 11:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CombiGene AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Niklas Elmhammer | Carlsquare AB |